HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML — Stella

Recruiting

Back to AML trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Blood Diseases Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Safety & dosing

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~60 participants

Started

January 2025

Primary completion

June 2026

Age range

60 Years – 75 Years

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov